B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
ABCL
AbCellera BiologicsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+0.1
Score
AI commentary
Headline tone improved after the May 11, 2026 earnings release because company-reported ABCL635 interim data were directionally supportive, and third-party coverage noted an immediate after-hours gain of about 7.7% on May 11. But by the May 13, 2026 anchor close of $4.77, that initial reaction had largely faded, and no clear delayed analyst target-reset cycle was found, which keeps this in cautious monitoring territory rather than a confirmed sentiment breakout.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-11catalystABCL635 interim Phase 1 data de-risked the program but left the main efficacy test aheadHigh impact
AbCellera reported that interim Phase 1 data for ABCL635 showed robust NK3R target engagement, favorable tolerability, and a pharmacokinetic profile that may support once-monthly dosing, supporting advancement into Phase 2; this improves setup versus the prior baseline, but the decisive efficacy proof point is still the Phase 2 readout rather than the just-reported biomarker data. [#8-K-2026-05-11]
2026-09-30eventQ3 2026 ABCL635 Phase 2 efficacy readout remains the key value inflectionHigh impact
Management said it looks forward to the Phase 2 efficacy readout for ABCL635 in Q3 2026 and framed it as a highly de-risking milestone for the pipeline pivot, making this the main medium-term catalyst after the post-earnings update. [#8-K-2026-05-11]
2026-12-31catalystLiquidity and 2026 pipeline execution can sustain multiple shots on goalHigh impact
AbCellera ended Q1 2026 with about $531 million of cash, cash equivalents, and marketable securities plus roughly $124 million of available non-dilutive government funding, or about $655 million of total available liquidity, while management said 2026 priorities include advancing ABCL688 and ABCL386 through IND-enabling work and selecting at least one additional development candidate. [#8-K-2026-05-11] [#10-Q-2026-05-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology